Resonance Health Ltd · ASX:RHT
Resonance Health — Investor Presentation (June 2018)
18 slides from Resonance Health's investor presentation, Jun 12, 2018
Slide 1: Corporate Presentation
Resonance Health Limited For personal use only CORPORATE PRESENTATION June 2018 | ASX: RHT
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Resonance Health Limited only and may contain forward-looking statements that are based on management’s current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to
Slide 3: Corporate Profile
Corporate Profile For personal use only Resonance Health (ASX: RHT) was founded in 2004 and is headquartered in Perth, Western Australia. RHT is an Australian healthcare company specialising in the development and delivery of non-invasive medical imaging software and analysis services. Our products
Slide 4: Financial Snapshot
Financial Snapshot Financial Highlights: For personal use only • Revenue for March quarter was $850K (unaudited), an increase of 31% versus the March quarter for previous year • Growth and profitability improvement continuous in Q3 2018 • 98% retention of top 50 customers • High repetition of busine
Slide 5: Financial Snapshot cont'd
Financial Snapshot cont’d For personal use only This highly stable, profitable platform provides an excellent base from which new initiatives can be undertaken. Resonance Health is actively pursuing opportunities for growth through both in-house innovation and potential collaborations with others, e
Slide 6: Iron Overload
For personal use only Iron Overload
Slide 7: Causes of Iron Overload
Causes of Iron Overload Anaemias and blood disorders Primary Iron Overload For personal use only requiring repeated blood transfusions: Hereditary Haemochromatosis • Inherited iron overload disorder • HH is the most common genetic disorder in western Thalassaemia populations affecting 1 in 250 peopl
Slide 8: FerriScan and Cardiac T2*
FerriScan and Cardiac T2* For personal use only Our Gold Standard MRI technology (FerriScan®) for liver iron concentration measurement alongside our Cardiac T2* MRI service has become established in many international ‘Standards of Care’ for Thalassemia. FerriScan is suitable for use in the quantifi
Slide 9: Global Access to FerriScan
Global Access to FerriScan For personal use only Map icons indicate just some of our FerriScan® locations, with over 400+ sites having now been activated.
Slide 10: FerriSmart
FerriSmart For personal use only FerriSmart® uses Artificial Intelligence (AI) incorporated into a fully automated computer software medical device to accurately and rapidly determine the liver iron concentration (LIC) from a specially acquired Magnetic Resonance (MR) image. FerriSmart® was designed
Slide 11: FerriScan & FerriSmart Target Markets
FerriScan & FerriSmart Target Markets For personal use only FerriScan FerriSmart
Slide 12: Metabolic Disease
Metabolic Disease For personal use only THE OBESITY EPIDEMIC Resonance Health has expanded its suite of products in the important metabolic disease space, with the Company now offering DR Grader alongside HepaFat Scan (for hepatic steatosis), pancreatic fat scan for pancreatic steatosis, NASH-Scan (
Slide 13: Metabolic Related Liver Disease
Metabolic Related Liver Disease For personal use only Rising global obesity, caused by the consumption of high calorie and nutrient poor diets, is increasing the rates of cardiovascular (heart) disease, diabetes, liver disease (NAFLD/NASH), and cancer. Non-alcoholic Fatty Liver Disease (NAFLD) Diabe
Slide 14: Metabolic Disease Products
Metabolic Disease Products For personal use only Resonance Health has recently increased its product suite with the inclusion of several new assessment techniques above to assist clinicians in diagnosing and managing conditions. It also offers additional services including: • Pancreatic Fat Assessme
Slide 15: TeleMedC (Diabetic Retinopathy)
TeleMedC (Diabetic Retinopathy) For personal use only • Resonance Health have signed a 2 year agency agreement to distribute an Artificial Intelligence (AI) Diabetic Retinopathy (DR) grading tool. • The technology, named DR Grader, was developed by leading researchers in Australia. • Dr Grader has b
Slide 16: Diabetes market in focus
Diabetes market in focus For personal use only Pakistan • 193 million people • 35 million to 37.5 million people above 20 are estimated to be suffering with diabetes • One study estimated the prevalence of DR in Pakistan at 26% Bangladesh • 163 million people • 1 in 4 at serious risk of losing their
Slide 17: Corporate Growth through Product Innovation and Collaboration
Corporate Growth through Product Innovation and Collaboration For personal use only Resonance Health is actively pursuing opportunities for growth through both in-house innovation and potential collaborations with others. Product Innovation: • 3T FerriScan calibration: Currently FerriScan is suitabl
Slide 18: Recent ASX Announcements
Recent ASX Announcements For personal use only • (4 May) Resonance Health sign 2-year agency agreement to distribute an Artificial Intelligence (AI) Diabetic Retinopathy (DR) grading tool. • (20 February) Resonance Health releases a new MRI-based assessment tool (NASHScan) for the screening of non-a